NNVC won't be dependent on outside funding to move thier Ebolacide program forward unless/until they have a potentail cure in hand with preclinical effectiveness demonstrated on an animal model.
Until that point - when scale-up would be required for human testing - they can produce what they need with existing facilities and with internal money. Once the Shelton plant is online - they may not even really need significant monetary input from outside sources at that point to be an effective medicine producer,.... although outside money would certainly grease the skids some.
They might even be able to do some Phase I level testing with the current facilities - once an effective set of ligands is found.
The biggest benefit to NNVC (and by proxy to us shareholders) if the Ebloacide program does produce a success is that as you point out in your point #3 - we get a demonstration of effectiveness of one of NNVC's compounds a bit earlier than it would be while waiting for Flucide to finish TOX testing and get some clinical tials under our belts.
This remains an interesting time - with some bits of risk remaining - to be a sharenolder here.
Whatever else you can say about what is going to be going on here through the end of 2015 - rest assured it won't be boring.
News 
Market Data 
Discover 
